LON:VAL - ValiRx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 1.35 -0.05 (-3.57 %)
(As of 11/18/2018 01:17 AM ET)
Previous CloseGBX 1.35
Today's RangeGBX 1.21 - GBX 1.40
52-Week RangeGBX 0.90 - GBX 7.75
Volume4.56 million shs
Average Volume3.82 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. It has licensing collaborations with Imperial Innovations Group plc, Cancer Research UK, and University College London Hospital. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.

Receive VAL News and Ratings via Email

Sign-up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:VAL
Previous Symbol
CUSIPN/A
Phone+44-20-30084416

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees12
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable

ValiRx (LON:VAL) Frequently Asked Questions

What is ValiRx's stock symbol?

ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

How were ValiRx's earnings last quarter?

ValiRx Plc (LON:VAL) posted its quarterly earnings data on Tuesday, April, 10th. The company reported ($1.90) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.60) by $0.70. View ValiRx's Earnings History.

What price target have analysts set for VAL?

1 equities research analysts have issued 12 month target prices for ValiRx's stock. Their forecasts range from £100,000 to GBX 0. On average, they expect ValiRx's stock price to reach GBX 0 in the next year. This suggests that the stock has a possible downside of 100.0%. View Analyst Price Targets for ValiRx.

What is the consensus analysts' recommendation for ValiRx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ValiRx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ValiRx.

Has ValiRx been receiving favorable news coverage?

News stories about VAL stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ValiRx earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of ValiRx's key competitors?

Who are ValiRx's key executives?

ValiRx's management team includes the folowing people:
  • Dr. Satu Vainikka, Founding Director & Chief Exec. Officer (Age 51)
  • Mr. James Gerry Desler, Founding Director & Chief Financial Officer (Age 62)
  • Dr. George Morris, Founding Director & Chief Operating Officer (Age 62)
  • Mr. Kevin Alexander, Sec. & Non-Exec. Director (Age 62)
  • Tarquin Edwards, Head of Communications

How do I buy shares of ValiRx?

Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ValiRx's stock price today?

One share of VAL stock can currently be purchased for approximately GBX 1.35.

What is ValiRx's official website?

The official website for ValiRx is http://www.valirx.com.

How can I contact ValiRx?

ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.


MarketBeat Community Rating for ValiRx (LON VAL)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about ValiRx and other stocks. Vote "Outperform" if you believe VAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel